Short Bowel Syndrome Market: Global Industry Analysis by Market Size, Share,Growth and Forecast 2023-2029


Global Short Bowel Syndrome Market size was valued at USD 1.53 Bn in 2022 and is expected to reach USD 4.29 Bn by 2029, at a CAGR of 15.9 %.

Short Bowel Syndrome Market Overview

Short bowel syndrome affect the functional ability of intestine. Patients suffering from short bowel syndrome have a decreased capability to absorb trace elements, vitamins, fats, fluids, minerals and carbohydrates and have experience weight loss, malnutrition, diarrhea and dehydration. Currently, there is no treatment for short bowel syndrome but the treatment is directed towards symptoms. In a rare cases, short bowel syndrome is life-threatening but usually, the disease is treated through effective medication. Treatment mostly comprises nutrition & diet management, medication and surgery.Short Bowel Syndrome Market

To know about the Research Methodology :- Request Free Sample Report

In treatment, Teduglutide was first permitted by the FDA for short bowel syndrome disorder and other treatments contain antidiarrheal, proton pump, inhibitors histamine blockers, and growth hormones.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The scope of the report includes a detailed study of global and regional markets for Short Bowel Syndrome with the reasons given for variants in the growth of the industry in certain regions.

Short Bowel Syndrome Market Dynamics

The short-bowled syndrome is a growth of problem-related to poor absorption of nutrients. The increasing prevalence of gastrointestinal diseases and surgeries is expected to drive the growth of the market. This "Optimist" is optimistic about the expanding patient pool, which fuel the demand for SBS treatments and therapies. The advancements in medical technology and the development of innovative therapies provide hope for improved outcomes and quality of life for individuals with Short Bowel Syndrome. Since, the rise in focus on personalized medicine and the development of tailored treatment options present opportunities for companies to develop targeted therapies that address the specific needs of SBS patients. Also, the growing investments in research and development and increasing collaborations between pharmaceutical companies and research institutions create a favorable environment for innovation and the Short Bowel Syndrome Market growth during the forecast period.

Growing awareness and convenience of epidemiological data lead to the improved controlling of short bowel disease. Additionally, rapid developments in the field of healthcare have raised awareness about short bowel syndrome and thus, creates opportunities in future. Similarly, non-profit organizations are encouraging research & development about short bowel syndrome in joint scientific research among the public and private sector. In relationship with non-profit organizations, state governments offer special incentives to manufacturers for the improvement of short bowel syndrome drugs.

Limited awareness and understanding of Short Bowel Syndrome among healthcare professionals and the general population to delay diagnosis and treatment initiation

The Realist recognizes the challenges associated with the Short Bowel Syndrome Market. One of the major challenges is the high cost of SBS treatments and therapies, which is expected to restrain the accessibility for some patients. Similarly, the complex nature of SBS and its management requires multidisciplinary approaches, involving gastroenterologists, surgeons, dieticians, and other specialists, posing logistical challenges in providing comprehensive care. The Realist understands that addressing these challenges is crucial for sustainable growth in the SBS market. The Pessimist is aware of the factors that may hinder the growth of the SBS market. Limited awareness and understanding of SBS among healthcare professionals and the general population can delay diagnosis and treatment initiation. The stringent regulatory requirements for drug approvals and the lengthy and expensive clinical trial process is expected to restrain the development and commercialization of new therapies. The Pessimist fears that these factors may hamper the overall market growth potential.

The expansion of short bowel syndrome drugs is at an emerging stage, which generates more opportunities for global players. Public-private partnerships are inspiring pharmaceutical companies to improve new orphan drugs for short bowel syndrome. Few countries have executed a combination of legislations, regulations, and policies indorsing drug development for short bowel syndrome. These are the potential drivers for the growth of the short bowel syndrome market. Instead of this, a lack of sanctioned treatment options may lead to the down regulate the growth of short bowel syndrome market.

Short Bowel Syndrome Market Segment Analysis

The report on Short Bowel Syndrome market covers segments such as by Drug Type, Distribution Channel and Region. The Drug Type segment includes Glucagon-like Peptide, Anti-Diarrheals, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, and Others. Among the Drug Type, Glucagon-like Peptide is accounted for the largest xx share in the Short Bowel Syndrome market. Currently, Glucagon-Like Peptide is leading the market because of its wide presence in the U.S. and Europe. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Specialty Pharmacies, and Others. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest xx% market share in the Short Bowel Syndrome market. The Hospital Pharmacies from Distribution Channel segment is anticipated to have a reasonable growth during the forecasted period.

Based on regional analysis, the Short Bowel Syndrome market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market during forecasted period. The rising prescriptions for Glucagon-like Peptide treatment in the U.S. is anticipated to driver the growth for the North America short bowel syndrome market. Additionally, the fact that glutamine and growth hormone are only permitted in the U.S. for treating SBS is anticipated to keep North America in the lead. The increasing awareness about short bowel syndrome amongst consumers and outstanding reimbursement strategies are anticipated to fuel the regional market during forecast period.

Competitive landscape

Key players operating in the Short Bowel Syndrome market are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, Zealand Pharma A/S, Swedish Orphan Biovitrum AB, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca Plc, and Johnson & Johnson. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the short Bowel Syndrome market growth.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Short Bowel Syndrome market dynamics, structure by identifying and analyzing the market segments and project the global market size. Also, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Short Bowel Syndrome market.

Scope of the Global Short Bowel Syndrome Market: Inquire before buying






Global Short Bowel Syndrome Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 1.53 Bn.




Forecast Period 2023 to 2029 CAGR:
15.9%
Market Size in 2029:
US $ 4.29 Bn.




 Segments Covered:
by Drug Type
• Glucagon-like Peptide
• Anti-Diarrheals
• Histamine Blockers
• Proton Pump Inhibitors
• Growth Hormone
• Others




by Distribution Channel
• Hospital Pharmacies
• Specialty Pharmacies
• Others.






Short Bowel Syndrome Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

Short Bowel Syndrome Market Key Players are:

• Ardelyx, Inc.
• Emmaus Life Sciences, Inc.
• GLyPharma Therapeutic, Inc.
• Merck KGaA
• Naia Pharmaceuticals, Inc.
• Nutrinia Ltd.
• OxThera, Sancilio & Company, Inc.
• Shire plc.
• Zealand Pharma A/S.
• Swedish Orphan Biovitrum AB.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• AstraZeneca Plc.
• Johnson & Johnson
• Biopharma, Inc.
• Adocia SAS
• Nestlé S.A.
• OPKO Health Inc.
• VectivBio AG

Frequently Asked questions

1. Which region has the largest share in Global Short Bowel Syndrome Market?
Ans: Asia Pacific region held the highest share in 2022.

2. What is the growth rate of Global Short Bowel Syndrome Market?
Ans: The Global Short Bowel Syndrome Market is growing at a CAGR of 15.9% during forecasting period 2023-2029.

3. What is scope of the Global Short Bowel Syndrome Market report?
Ans: Global Short Bowel Syndrome Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Short Bowel Syndrome Market?
Ans: The important key players in the Global Short Bowel Syndrome Market are – Ardelyx, Inc.,Emmaus Life Sciences, Inc.,GLyPharma Therapeutic, Inc.,Merck KGaA,Naia Pharmaceuticals, Inc.,Nutrinia Ltd.,OxThera, Sancilio & Company, Inc.,Shire plc.,Zealand Pharma A/S.,Swedish Orphan Biovitrum AB.,Novartis AG.

5. What is the study period of this Market?
Ans: The Global Short Bowel Syndrome Market is studied from 2022 to 2029. 




Short Bowel Syndrome Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Short Bowel Syndrome Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Short Bowel Syndrome Market Analysis and Forecast
6.1. Global Short Bowel Syndrome Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Short Bowel Syndrome Market Analysis and Forecast, By Drug Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Short Bowel Syndrome Market Value Share Analysis, By Drug Type
7.4. Global Short Bowel Syndrome Market Size (US$ Bn) Forecast, By Drug Type
7.5. Global Short Bowel Syndrome Market Analysis, By Drug Type
7.6. Global Short Bowel Syndrome Market Attractiveness Analysis, By Drug Type
8. Short Bowel Syndrome Market Analysis and Forecast, By Distribution Channel
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Short Bowel Syndrome Market Value Share Analysis, By Distribution Channel
8.4. Global Short Bowel Syndrome Market Size (US$ Bn) Forecast, By Distribution Channel
8.5. Global Short Bowel Syndrome Market Analysis, By Distribution Channel
8.6. Global Short Bowel Syndrome Market Attractiveness Analysis, By Distribution Channel
9. Short Bowel Syndrome Market Analysis, by Region
9.1. Global Short Bowel Syndrome Market Value Share Analysis, by Region
9.2. Global Short Bowel Syndrome Market Size (US$ Bn) Forecast, by Region
9.3. Global Short Bowel Syndrome Market Attractiveness Analysis, by Region
10. North America Short Bowel Syndrome Market Analysis
10.1. Key Findings
10.2. North America Short Bowel Syndrome Market Overview
10.3. North America Short Bowel Syndrome Market Value Share Analysis, By Drug Type
10.4. North America Short Bowel Syndrome Market Forecast, By Drug Type
10.4.1. Glucagon-like Peptide
10.4.2. Anti-Diarrheals
10.4.3. Histamine Blockers
10.4.4. Proton Pump Inhibitors
10.4.5. Growth Hormone
10.4.6. Others
10.5. North America Short Bowel Syndrome Market Value Share Analysis, By Distribution Channel
10.6. North America Short Bowel Syndrome Market Forecast, By Distribution Channel
10.6.1. Hospital Pharmacies
10.6.2. Specialty Pharmacies
10.6.3. Others.
10.7. North America Short Bowel Syndrome Market Value Share Analysis, by Country
10.8. North America Short Bowel Syndrome Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Short Bowel Syndrome Market Analysis, by Country
10.10. U.S. Short Bowel Syndrome Market Forecast, By Drug Type
10.10.1. Glucagon-like Peptide
10.10.2. Anti-Diarrheals
10.10.3. Histamine Blockers
10.10.4. Proton Pump Inhibitors
10.10.5. Growth Hormone
10.10.6. Others
10.11. U.S. Short Bowel Syndrome Market Forecast, By Distribution Channel
10.11.1. Hospital Pharmacies
10.11.2. Specialty Pharmacies
10.11.3. Others.
10.12. Canada Short Bowel Syndrome Market Forecast, By Drug Type
10.12.1. Glucagon-like Peptide
10.12.2. Anti-Diarrheals
10.12.3. Histamine Blockers
10.12.4. Proton Pump Inhibitors
10.12.5. Growth Hormone
10.12.6. Others
10.13. Canada Short Bowel Syndrome Market Forecast, By Distribution Channel
10.13.1. Hospital Pharmacies
10.13.2. Specialty Pharmacies
10.13.3. Others.
10.14. North America Short Bowel Syndrome Market Attractiveness Analysis
10.14.1. By Drug Type
10.14.2. By Distribution Channel
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Developments
11. Europe Short Bowel Syndrome Market Analysis
11.1. Key Findings
11.2. Europe Short Bowel Syndrome Market Overview
11.3. Europe Short Bowel Syndrome Market Value Share Analysis, By Drug Type
11.4. Europe Short Bowel Syndrome Market Forecast, By Drug Type
11.4.1. Glucagon-like Peptide
11.4.2. Anti-Diarrheals
11.4.3. Histamine Blockers
11.4.4. Proton Pump Inhibitors
11.4.5. Growth Hormone
11.4.6. Others
11.5. Europe Short Bowel Syndrome Market Value Share Analysis, By Distribution Channel
11.6. Europe Short Bowel Syndrome Market Forecast, By Distribution Channel
11.6.1. Hospital Pharmacies
11.6.2. Specialty Pharmacies
11.6.3. Others.
11.7. Europe Short Bowel Syndrome Market Value Share Analysis, by Country
11.8. Europe Short Bowel Syndrome Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Short Bowel Syndrome Market Analysis, by Country
11.10. Germany Short Bowel Syndrome Market Forecast, By Drug Type
11.10.1. Glucagon-like Peptide
11.10.2. Anti-Diarrheals
11.10.3. Histamine Blockers
11.10.4. Proton Pump Inhibitors
11.10.5. Growth Hormone
11.10.6. Others
11.11. Germany Short Bowel Syndrome Market Forecast, By Distribution Channel
11.11.1. Hospital Pharmacies
11.11.2. Specialty Pharmacies
11.11.3. Others.
11.12. U.K. Short Bowel Syndrome Market Forecast, By Drug Type
11.12.1. Glucagon-like Peptide
11.12.2. Anti-Diarrheals
11.12.3. Histamine Blockers
11.12.4. Proton Pump Inhibitors
11.12.5. Growth Hormone
11.12.6. Others
11.13. U.K. Short Bowel Syndrome Market Forecast, By Distribution Channel
11.13.1. Hospital Pharmacies
11.13.2. Specialty Pharmacies
11.13.3. Others.
11.14. France Short Bowel Syndrome Market Forecast, By Drug Type
11.14.1. Glucagon-like Peptide
11.14.2. Anti-Diarrheals
11.14.3. Histamine Blockers
11.14.4. Proton Pump Inhibitors
11.14.5. Growth Hormone
11.14.6. Others
11.15. France Short Bowel Syndrome Market Forecast, By Distribution Channel
11.15.1. Hospital Pharmacies
11.15.2. Specialty Pharmacies
11.15.3. Others.
11.16. Italy Short Bowel Syndrome Market Forecast, By Drug Type
11.16.1. Glucagon-like Peptide
11.16.2. Anti-Diarrheals
11.16.3. Histamine Blockers
11.16.4. Proton Pump Inhibitors
11.16.5. Growth Hormone
11.16.6. Others
11.17. Italy Short Bowel Syndrome Market Forecast, By Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Specialty Pharmacies
11.17.3. Others.
11.18. Spain Short Bowel Syndrome Market Forecast, By Drug Type
11.18.1. Glucagon-like Peptide
11.18.2. Anti-Diarrheals
11.18.3. Histamine Blockers
11.18.4. Proton Pump Inhibitors
11.18.5. Growth Hormone
11.18.6. Others
11.19. Spain Short Bowel Syndrome Market Forecast, By Distribution Channel
11.19.1. Hospital Pharmacies
11.19.2. Specialty Pharmacies
11.19.3. Others.
11.20. Rest of Europe Short Bowel Syndrome Market Forecast, By Drug Type
11.20.1. Glucagon-like Peptide
11.20.2. Anti-Diarrheals
11.20.3. Histamine Blockers
11.20.4. Proton Pump Inhibitors
11.20.5. Growth Hormone
11.20.6. Others
11.21. Rest of Europe Short Bowel Syndrome Market Forecast, By Distribution Channel
11.21.1. Hospital Pharmacies
11.21.2. Specialty Pharmacies
11.21.3. Others.
11.22. Europe Short Bowel Syndrome Market Attractiveness Analysis
11.22.1. By Drug Type
11.22.2. By Distribution Channel
11.23. PEST Analysis
11.24. Key Trends
11.25. Key Developments
12. Asia Pacific Short Bowel Syndrome Market Analysis
12.1. Key Findings
12.2. Asia Pacific Short Bowel Syndrome Market Overview
12.3. Asia Pacific Short Bowel Syndrome Market Value Share Analysis, By Drug Type
12.4. Asia Pacific Short Bowel Syndrome Market Forecast, By Drug Type
12.4.1. Glucagon-like Peptide
12.4.2. Anti-Diarrheals
12.4.3. Histamine Blockers
12.4.4. Proton Pump Inhibitors
12.4.5. Growth Hormone
12.4.6. Others
12.5. Asia Pacific Short Bowel Syndrome Market Value Share Analysis, By Distribution Channel
12.6. Asia Pacific Short Bowel Syndrome Market Forecast, By Distribution Channel
12.6.1. Hospital Pharmacies
12.6.2. Specialty Pharmacies
12.6.3. Others.
12.7. Asia Pacific Short Bowel Syndrome Market Value Share Analysis, by Country
12.8. Asia Pacific Short Bowel Syndrome Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Short Bowel Syndrome Market Analysis, by Country
12.10. China Short Bowel Syndrome Market Forecast, By Drug Type
12.10.1. Glucagon-like Peptide
12.10.2. Anti-Diarrheals
12.10.3. Histamine Blockers
12.10.4. Proton Pump Inhibitors
12.10.5. Growth Hormone
12.10.6. Others
12.11. China Short Bowel Syndrome Market Forecast, By Distribution Channel
12.11.1. Hospital Pharmacies
12.11.2. Specialty Pharmacies
12.11.3. Others.
12.12. India Short Bowel Syndrome Market Forecast, By Drug Type
12.12.1. Glucagon-like Peptide
12.12.2. Anti-Diarrheals
12.12.3. Histamine Blockers
12.12.4. Proton Pump Inhibitors
12.12.5. Growth Hormone
12.12.6. Others
12.13. India Short Bowel Syndrome Market Forecast, By Distribution Channel
12.13.1. Hospital Pharmacies
12.13.2. Specialty Pharmacies
12.13.3. Others.
12.14. Japan Short Bowel Syndrome Market Forecast, By Drug Type
12.14.1. Glucagon-like Peptide
12.14.2. Anti-Diarrheals
12.14.3. Histamine Blockers
12.14.4. Proton Pump Inhibitors
12.14.5. Growth Hormone
12.14.6. Others
12.15. Japan Short Bowel Syndrome Market Forecast, By Distribution Channel
12.15.1. Hospital Pharmacies
12.15.2. Specialty Pharmacies
12.15.3. Others.
12.16. ASEAN Short Bowel Syndrome Market Forecast, By Drug Type
12.16.1. Glucagon-like Peptide
12.16.2. Anti-Diarrheals
12.16.3. Histamine Blockers
12.16.4. Proton Pump Inhibitors
12.16.5. Growth Hormone
12.16.6. Others
12.17. ASEAN Short Bowel Syndrome Market Forecast, By Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Specialty Pharmacies
12.17.3. Others.
12.18. Rest of Asia Pacific Short Bowel Syndrome Market Forecast, By Drug Type
12.18.1. Glucagon-like Peptide
12.18.2. Anti-Diarrheals
12.18.3. Histamine Blockers
12.18.4. Proton Pump Inhibitors
12.18.5. Growth Hormone
12.18.6. Others
12.19. Rest of Asia Pacific Short Bowel Syndrome Market Forecast, By Distribution Channel
12.19.1. Hospital Pharmacies
12.19.2. Specialty Pharmacies
12.19.3. Others.
12.20. Asia Pacific Short Bowel Syndrome Market Attractiveness Analysis
12.20.1. By Drug Type
12.20.2. By Distribution Channel
12.21. PEST Analysis
12.22. Key Trends
12.23. Key Developments
13. Middle East & Africa Short Bowel Syndrome Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Short Bowel Syndrome Market Overview
13.3. Middle East & Africa Short Bowel Syndrome Market Value Share Analysis, By Drug Type
13.4. Middle East & Africa Short Bowel Syndrome Market Forecast, By Drug Type
13.4.1. Glucagon-like Peptide
13.4.2. Anti-Diarrheals
13.4.3. Histamine Blockers
13.4.4. Proton Pump Inhibitors
13.4.5. Growth Hormone
13.4.6. Others
13.5. Middle East & Africa Short Bowel Syndrome Market Value Share Analysis, By Distribution Channel
13.6. Middle East & Africa Short Bowel Syndrome Market Forecast, By Distribution Channel
13.6.1. Hospital Pharmacies
13.6.2. Specialty Pharmacies
13.6.3. Others.
13.7. Middle East & Africa Short Bowel Syndrome Market Value Share Analysis, by Country
13.8. Middle East & Africa Short Bowel Syndrome Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Short Bowel Syndrome Market Analysis, by Country
13.10. GCC Short Bowel Syndrome Market Forecast, By Drug Type
13.10.1. Glucagon-like Peptide
13.10.2. Anti-Diarrheals
13.10.3. Histamine Blockers
13.10.4. Proton Pump Inhibitors
13.10.5. Growth Hormone
13.10.6. Others
13.11. GCC Short Bowel Syndrome Market Forecast, By Distribution Channel
13.11.1. Hospital Pharmacies
13.11.2. Specialty Pharmacies
13.11.3. Others.
13.12. South Africa Short Bowel Syndrome Market Forecast, By Drug Type
13.12.1. Glucagon-like Peptide
13.12.2. Anti-Diarrheals
13.12.3. Histamine Blockers
13.12.4. Proton Pump Inhibitors
13.12.5. Growth Hormone
13.12.6. Others
13.13. South Africa Short Bowel Syndrome Market Forecast, By Distribution Channel
13.13.1. Hospital Pharmacies
13.13.2. Specialty Pharmacies
13.13.3. Others.
13.14. Rest of Middle East & Africa Short Bowel Syndrome Market Forecast, By Drug Type
13.14.1. Glucagon-like Peptide
13.14.2. Anti-Diarrheals
13.14.3. Histamine Blockers
13.14.4. Proton Pump Inhibitors
13.14.5. Growth Hormone
13.14.6. Others
13.15. Rest of Middle East & Africa Short Bowel Syndrome Market Forecast, By Distribution Channel
13.15.1. Hospital Pharmacies
13.15.2. Specialty Pharmacies
13.15.3. Others.
13.16. Middle East & Africa Short Bowel Syndrome Market Attractiveness Analysis
13.16.1. By Drug Type
13.16.2. By Distribution Channel
13.17. PEST Analysis
13.18. Key Trends
13.19. Key Developments
14. South America Short Bowel Syndrome Market Analysis
14.1. Key Findings
14.2. South America Short Bowel Syndrome Market Overview
14.3. South America Short Bowel Syndrome Market Value Share Analysis, By Drug Type
14.4. South America Short Bowel Syndrome Market Forecast, By Drug Type
14.4.1. Glucagon-like Peptide
14.4.2. Anti-Diarrheals
14.4.3. Histamine Blockers
14.4.4. Proton Pump Inhibitors
14.4.5. Growth Hormone
14.4.6. Others
14.5. South America Short Bowel Syndrome Market Value Share Analysis, By Distribution Channel
14.6. South America Short Bowel Syndrome Market Forecast, By Distribution Channel
14.6.1. Hospital Pharmacies
14.6.2. Specialty Pharmacies
14.6.3. Others.
14.7. South America Short Bowel Syndrome Market Value Share Analysis, by Country
14.8. South America Short Bowel Syndrome Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. South America Short Bowel Syndrome Market Analysis, by Country
14.10. Brazil Short Bowel Syndrome Market Forecast, By Drug Type
14.10.1. Glucagon-like Peptide
14.10.2. Anti-Diarrheals
14.10.3. Histamine Blockers
14.10.4. Proton Pump Inhibitors
14.10.5. Growth Hormone
14.10.6. Others
14.11. Brazil Short Bowel Syndrome Market Forecast, By Distribution Channel
14.11.1. Hospital Pharmacies
14.11.2. Specialty Pharmacies
14.11.3. Others.
14.12. Mexico Short Bowel Syndrome Market Forecast, By Drug Type
14.12.1. Glucagon-like Peptide
14.12.2. Anti-Diarrheals
14.12.3. Histamine Blockers
14.12.4. Proton Pump Inhibitors
14.12.5. Growth Hormone
14.12.6. Others
14.13. Mexico Short Bowel Syndrome Market Forecast, By Distribution Channel
14.13.1. Hospital Pharmacies
14.13.2. Specialty Pharmacies
14.13.3. Others.
14.14. Rest of South America Short Bowel Syndrome Market Forecast, By Drug Type
14.14.1. Glucagon-like Peptide
14.14.2. Anti-Diarrheals
14.14.3. Histamine Blockers
14.14.4. Proton Pump Inhibitors
14.14.5. Growth Hormone
14.14.6. Others
14.15. Rest of South America Short Bowel Syndrome Market Forecast, By Distribution Channel
14.15.1. Hospital Pharmacies
14.15.2. Specialty Pharmacies
14.15.3. Others.
14.16. South America Short Bowel Syndrome Market Attractiveness Analysis
14.16.1. By Drug Type
14.16.2. By Distribution Channel
14.17. PEST Analysis
14.18. Key Trends
14.19. Key Developments
15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Route of Administrations and R&D investment
15.2.2. New Treatment Center Launches and Treatment Center Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Route of Administrations
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration
15.3. Company Profiles: Key Players
15.3.1. Ardelyx, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Treatment Center Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Emmaus Life Sciences, Inc.
15.3.3. GLyPharma Therapeutic, Inc.
15.3.4. Merck KGaA
15.3.5. Naia Pharmaceuticals, Inc.
15.3.6. Nutrinia Ltd.
15.3.7. OxThera, Sancilio & Company, Inc.
15.3.8. Shire plc.
15.3.9. Zealand Pharma A/S.
15.3.10. Swedish Orphan Biovitrum AB.
15.3.11. Novartis AG
15.3.12. Pfizer Inc.
15.3.13. Teva Pharmaceutical Industries Ltd.
15.3.14. Mylan N.V.
15.3.15. AstraZeneca Plc.
15.3.16. Johnson & Johnson
15.3.17. Biopharma, Inc.
15.3.18. Adocia SAS
15.3.19. Nestlé S.A.
15.3.20. OPKO Health Inc.
15.3.21. VectivBio AG

16. Primary Key Insights
  • INQUIRE BEFORE BUYING